Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
- Author:
Hundo CHO
1
;
Jin-Hyuk CHOI
;
Seok Yun KANG
;
Hyun Woo LEE
;
Yong Won CHOI
;
Tae-Hwan KIM
;
Mi Sun AHN
;
Chul-Ho KIM
;
Yoo Seob SHIN
;
Jeon Yeob JANG
;
Young-Taek OH
;
Jaesung HEO
;
Seung Soo SHEEN
Author Information
- Publication Type:2
- From:The Korean Journal of Internal Medicine 2022;37(3):653-659
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence
Methods:Two hundred and fifty-seven patients who started CCRT with cisplatin for H&N cancer from January 2005 to December 2019 were analyzed.
Results:TEE occurred in five patients, an incidence rate of 1.9%. The 2-, 4-, and 6-month cumulative incidences of TEE were 0.8%, 1.6%, and 1.9%, respectively. Khorana score was the only factor associated with TEE occurrence (p = 0.010).
Conclusions:The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.
